临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1986-47-6

Tranylcypromine (2-PCPA) HCl

中文名称:反式-2-苯基环丙胺盐酸盐
CAS号:1986-47-6
分子式: C9H12ClN 分子量: 169.65
产品形式: Hydrochloride
研发状态: Completed
研发用途: Major Depressive Disorder; Treatment Resistant Depression
研究机构: Centre for Addiction and Mental Health
研发日期: April 15 2021
研发阶段: Not Applicable
Tranylcypromine HCl (2-PCPA, SKF-385, Parnate) is a monoamine oxidase inhibitor, which inhibits CYP2A6 with Ki of 0.08 μM and 0.2 μM in cDNA-expressing microsomes and Human Liver Microsomes, respectively.

CAS: 198481-33-3

Bazedoxifene (TSE-424) acetate

中文名称:醋酸巴多昔芬
CAS号:198481-33-3
分子式: C30H34N2O3.C2H4O2 分子量: 530.65
产品形式: Acetate
研发状态: Unknown status
研发用途: Osteoporosis Postmenopausal
研究机构: Huons Co. Ltd.
研发日期: January 11 2018
研发阶段: Phase 1
Bazedoxifene Acetate (WAY-140424,TSE-424 acetate) is a third generation selective estrogen receptor modulator (SERM).

CAS: 198480-56-7

Bazedoxifene (WAY-140424) HCl

中文名称:盐酸巴多昔芬
CAS号:198480-56-7
分子式: C30H34N2O3.HCl 分子量: 507.06
产品形式: Hydrochloride
研发状态: Unknown status
研发用途: Osteoporosis Postmenopausal
研究机构: Huons Co. Ltd.
研发日期: January 11 2018
研发阶段: Phase 1
Bazedoxifene HCl (WAY-140424, TSE-424) is a novel, non-steroidal, indole-based estrogen receptor modulator (SERM) binding to both ERα and ERβ with IC50 of 23 nM and 89 nM, respectively.

CAS: 19774-82-4

Amiodarone (NSC 85442) HCl

中文名称:盐酸胺碘酮
CAS号:19774-82-4
分子式: C25H29I2NO3.HCl 分子量: 681.77
产品形式: Hydrochloride
研发状态: Not yet recruiting
研发用途: Atrial Fibrillation; Esophageal Carcinoma
研究机构: OHSU Knight Cancer Institute
研发日期: May 1 2024
研发阶段: Phase 2
Amiodarone (NSC 85442,Amiodar,Amiodarone hydrochloride,Nexterone) HCl is a sodium/potassium-ATPase inhibitor and an autophagy activator, used to treat various types of cardiac dysrhythmias.

CAS: 19767-45-4

Mesna

中文名称:美司那
CAS号:19767-45-4
分子式: C2H5NaO3S2 分子量: 164.18
产品形式: Sodium Salt
研发状态: Completed
研发用途: Obesity; Drug Effect
研究机构: University of Oslo; Oslo University Hospital; University of Oxford
研发日期: November 2 2020
研发阶段: Phase 1
Mesna, a sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.

CAS: 1971920-73-6

Tolebrutinib (SAR442168)

中文名称:(R)-1-(1-丙烯酰基哌啶-3-基)-4-氨基-3-(4-苯氧基苯基)-1H-咪唑并[4,5-C]吡啶-2(3H)-酮
CAS号:1971920-73-6
分子式: C₂₆H₂₅N₅O₃ 分子量: 455.51
产品形式: Free base
研发状态: Completed
研发用途: Hepatic Function Abnormal
研究机构: Sanofi
研发日期: March 18 2022
研发阶段: Phase 1
Tolebrutinib (SAR442168, PRN2246, BTKi'168, BTKi('168)) is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine kinase (BTK) with IC50s of 0.4 nM and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively.